Strategic question
Where is pan-omics innovation concentrated across Europe and Asia, and which ventures warrant deeper engagement?
How Galen Growth helped
From market signal to decision-ready evidence
Using HealthTech Alpha, we evaluated 264 ventures across two regional ecosystems, applied client criteria to prioritise 63, and mapped strategic partnerships in detail to surface the most engagement-ready.
Outcomes
Turned an opaque, fast-moving pan-omics space into a structured, comparative map of strategic relevance.
Decision enabled: Enabled the biotech to focus partnership and licensing engagement on a defensible prioritised set.
Key results
Our approach
A repeatable path to a defensible decision
Define
Clarify the strategic question, decision owner, market boundaries, and success criteria.
Map
Identify the relevant ventures, markets, competitors, partnerships, and evidence signals.
Assess
Evaluate maturity, traction, clinical relevance, commercial fit, and operational readiness.
Decide
Translate the evidence into a shortlist, benchmark, market view, or portfolio recommendation.
Related work
More digital health case studies
Tracking Competitor Moves to Support Global Franchise Strategy
How should we track competitor activity across obesity, diabetes and cardiovascular disease to support global strategic decisions?
Prioritising Markets and Partners to Accelerate a Women’s Health Roadmap
Which priority markets and venture partners should anchor our future women’s health innovation roadmap, starting with telemedicine?
Benchmarking Global Competitor Partnerships to Prioritise Digital Health Strategy
Where are competitors investing and partnering in Digital Health, and what should that mean for our own portfolio strategy?